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Available online 28 December 2015Human lymphoblast cells from a male patient diagnosed with Alzheimer's disease (AD) expressing the TREM2
p.R47H variant were used to generate integration-free induced pluripotent stem (iPS) cells employing episomal
plasmids expressing OCT4, SOX2, NANOG, LIN28, c-MYC and L-MYC. The iPS cells retained the TREM2mutation,
and were deﬁned as pluripotent based on (i) expression of pluripotent-associated markers, (ii) embryoid body-
based differentiation into cell types representative of the three germ layers and (iii) the similarity between the
transcriptomes of the iPS cell line and the human embryonic stem cell lineH1with a Pearson correlation of 0.966.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).In
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Lymphoblast cells (AD2-2), derived from a 65-year-old AD patient ex-
pressing the TREM2 missense p.R47H mutation (Cuyvers et al., 2014),
were reprogrammed employing oriP/EBNA-1-based episomal plasmids
expressing OCT4, SOX2, KLF4, C-MYC, L-MYC, LIN28 and a p53 shRNA.
After picking the clones, clone A of Lymph2-AD2-iPS cell line retained
traces of EBNA1 (Fig. 1A) but was diluted out after several passages
(data not shown). Clone B was negative for EBNA-1 and oriP (Fig. 1A),
but both clones were positive for the pluripotency-associated genes
OCT4, SOX2, NANOG and TGDF1 (Fig. 1A). Pluripotency was conﬁrmed
by (i) expression of OCT4, SOX2, NANOG, TRA-1-60 and TRA-1-81 and
SSEA4 (Fig. 1B) and (ii) embryoid body (EB)-based spontaneous differen-
tiation into cell types representative of the three germ layers, namely ec-
toderm (Nestin, PAX6), mesoderm (SMA — smooth muscle actin) and
endoderm (AFP— α-feto protein, SOX17) (Fig. 1C).
The DNA ﬁngerprint of Lymph2-AD2-iPS cell line was identical to the
parental lymphoblast line AD2-2 (Fig. 1D). Karyotype analysis was male
(XY) and both lines exhibited a normal diploid chromosomal content
(Fig. 1E). As depicted in the Dendrogram (Fig. 1F), the transcriptome of
the parental lymphoblast cells differs from the pluripotent cell lines. The
transcriptomes of the Lymph2-AD2-iPS cells and the embryonic stemp://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Characterization of the Lymph2-AD2-iPS line. (A) Conﬁrmation ofmRNA expression of pluripotency-associated, oriP and EBNA-1 genes. NTC and control are the same as described in
Schröter et al., (2016); NTC, non-template control; Ctrl, control linewith oriP and EBNA-1 detection. (B) Immunoﬂuorescence-based detection of human pluripotency-associated proteins
OCT4, SOX2, NANOGand surfacemarkers TRA-1-60, TRA-1-81 and SSEA4. Hoechst 33,258was used for the nuclei staining. Scale bar: big— 150 μm, small— 30 μm. (C) Embryoid body (EB)
formationwas induced in Lymph2-AD2-iPS cells in vitro and analyzed by immunoﬂuorescence-based detection of different germ layer marker: ectoderm—Nestin, PAX6;mesoderm—α-
smooth muscle actin (SMA) and endoderm— α-Feto Protein (AFP), SOX17. Scale bar: EBs — 150 μm, germ layer — 30 μm. (D) Gel electrophoresis of DNA ﬁngerprinting PCR products.
Genomic DNA was isolated from parental lymphoblast cells AD2-2, Lymph2-AD2-iPS cells (separated into two clones, A and B) and embryonic stem cell line H1. DNA was ampliﬁed
using PCR primers that ﬂank different genomic regions (D7S796, D17S1290 and D21S2055). (E) Karyotyping analysis of parental lymphoblast AD2-2 and Lymph2-AD2-iPS line.
Presence of male karyogram 46, XY. (F) Cluster Dendrogram of lymphoblast AD2-2, Lymph2-AD2-iPS line and embryonic stem cell line H1. (G) Sequence trace of control CEPH (ﬁrst
line), Lymph2-AD2-iPS (middle) and parental lymphoblast AD2-2 (last) DNA. The TREM2 missense mutation p.R47H results from a single base substitution (G N A) (black arrow).
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115F. Schröter et al. / Stem Cell Research 16 (2016) 113–115cell line-H1, clustered together with a Pearson correlation of 0.966. The
reprogramming process did not alter the TREM2 missense mutation as
demonstrated in Fig. 1G.
3. Materials and methods
3.1. Ethic statements
The EBV-transformed lymphoblastoid cell line, AD2-2, used for the
generation of the iPS cell line Lymph2-AD2,was generated fromperiph-
eral blood lymphocytes from a 65-year-old male donor diagnosed with
Alzheimer's disease. The research protocol was approved by the Ethics
Committee of the University Hospital Antwerp and the University of
Antwerp, Belgium.
3.2. Cell culture
The lymphoblast cell line AD2-2 (Cuyvers et al., 2014) was cultured
in RPMI1640 supplementedwith15% fetal bovine serum(Invitrogen™),
1% GlutaMAX (Invitrogen™), 1% Sodium pyruvate (Invitrogen™) and
1% Penicillin/Streptomycin (Invitrogen™) at 37 °C and 5% CO2.
3.3. Derivation of the iPS cell line
Lymphoblast cells (AD2-2) were reprogrammed by nucleofection of
oriP/EBNA-1-based episomal plasmids (expressing OCT4, SOX2, KLF4,
L-MYC, LIN28 and a p53 shRNA) (Okita et al., 2011) at the Biomedicum
Stem Cell Center, University of Helsinki, Finland, (http://research.med.
helsinki.ﬁ/neuro/Otonkoski/core/default.html) as a service. The iPS
cells were cultured under feeder-free conditions on Matrigel®-coated
plates in E8 medium (Invitrogen™).
3.4. Polymerase chain reaction
RT-PCR to assess the expression levels of the transgene and endoge-
nous stem cell markers were carried out by the Biomedicum Stem Cell
Center, University of Helsinki, Finland.
3.5. Embryoid body formation
Embryoid body (EB) formationwas carried out as described in (Matz
and Adjaye, 2015). In brief, after culturing of the iPS cells in ultra-low
attachment ﬂask (Corning) in FDTA medium, the EBs were replated
onto gelatin-coated plates, again in FDTA medium lacking bFGF and
Dorsomorphin (Frank et al., 2012).
3.6. Immunocytochemistry
Immunocytochemistry was performed as described in (Schröter
et al., 2016), except for the germ layers staining. The following antibod-
ies were used: rabbit anti-Nestin (Sigma Aldrich; 1:1000), mouse anti-
PAX6 (SYSY, 1:1000), mouse anti-SMA (Cell Signaling; 1:1000), rabbit
anti-AFP (Sigma Aldrich; 1:500) and mouse anti-SOX17 (Novus Biolog-
ical, 1:500). The ﬂuorescent images obtained by an inverse ﬂuorescence
microscope LSM 700 (Carl Zeiss) and analyzed employing Adobe
Photoshop software (Adobe, USA).
3.7. Karyotype analysis
Karyotype analysis was evaluated and performed at the Institute of
Human Genetics and Anthropology, Heinrich-Heine-University,
Düsseldorf. Thirty and twelve metaphases were counted for theparental lymphoblast line AD2-2 and the iPS cell line Lymph2-AD2,
respectively.
3.8. DNA ﬁngerprinting
Genomic DNA was isolated according to the manufacturer protocol
from the lymphoblast line AD2-2, the Lymph2-AD2-iPS line, separated
in two independent lines A and B, and the human embryonic stem cell
line (H1). The STR analysis was performed by PCR ampliﬁcation with
speciﬁc primers (Prigione et al., 2011; Wang and Adjaye, 2011).
3.9. Bidirectional Sanger sequencing
Genotyping of TREM2 p.R47Hwas performed on genomic DNA from
the lymphoblast line AD2-2 and the Lymph2-AD2-iPS line by PCR am-
pliﬁcation and Sanger sequencing of exon 2 as described in Cuyvers
et al. (2014).
3.10. RNA-based microarray analysis
RNA-based microarray analysis was performed as described in
Schröter et al. (2016). Microarray analysis was outsourced to the
Genomics/Transcriptomic Laboratory of the BMFZ, Heinrich-Heine-
University, Düsseldorf.
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